QurAlis Presents! Hagen Cramer, QurAlis' chief technology officer, and Huijun Tian, director, analytical development and quality control, will be featured speakers at the 3rd Annual #Oligonucleotide CMC & Analytical Development Summit taking place this week 8/27-8/29 in Boston. Hagen will participate in the session entitled, "Dynamic Journeys: Defining CQA for Oligonucleotide Therapeutics" on Tuesday, 8/27 at 8aET (Workshop A). Tian will present, "Balancing Resolution & Equipment Complexity to Streamline Transfer to CMC Teams" on Thursday, 8/29 at 9aET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/4fQrzXT
QurAlis
Biotechnology
Cambridge, MA 8,656 followers
Neuro Pioneers on a Quest to Cure
About us
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
- Website
-
https://quralis.com/
External link for QurAlis
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- ALS, FTD, ALS Genes, ALS Drug, Precision Therapy, and Precision Medicine
Locations
-
Primary
100 Cambridge Park Drive
5th Floor
Cambridge, MA 02140, US
Employees at QurAlis
-
Kevin Eggan
-
Anne Whitaker
Independent Director | Private Equity and Board Advisor l Board of Directors Chairwoman l Experienced Biotech CEO and Large Pharma C-Suite Leader
-
Emma Bowden
Vice President, Head of Clinical Development at QurAlis
-
Vikas Sharma
Chief Business Officer @ QurAlis | Entrepreneur | Company builder
Updates
-
QurAlis reposted this
QurAlis is thrilled to be named one of the top 10 neuroscience biotechs by Labiotech.eu. It is an honor to be recognized for the work we are doing to help discover and develop effective #precisionmedicines that have the potential to alter the trajectory of #ALS, #FTD, and other #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3MzZ5Ep
10 neuroscience biotech companies you should know about
https://www.labiotech.eu
-
QurAlis is proud to sponsor the 3rd Australia and New Zealand #MND Research Symposium being held 8/27-8/28 at The Florey Institute in Melbourne, Australia. #ALS #precisionmedicine #neurodegenerativediseases #neurologicaldisease https://lnkd.in/gjV9NGUb
Welcome
mndresearchsymposium.org.au
-
QurAlis' #STATHMIN-2 (#STMN2) program - QRL-201 - is featured in Target ALS' recent blog that shares insights into advancements in #ALS drug discovery and development. The blog highlights the 'cutting-edge research funded by Target ALS and its significant impact on the current and future clinical trial landscape.' QRL-201 is a first-in-class #precisionmedicine product candidate that aims to restore STMN2 expression in ALS patients. QRL-201 is being evaluated in the Phase I ANQUR clinical trial - the first-ever study to evaluate a potential therapy to rescue STMN2 expression in ALS patients. #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3SZCNQ1
ALS Drug Discovery and Development: a Glimpse into the Future
https://www.targetals.org
-
QurAlis' CEO and founder Kasper Roet will present a corporate overview at the 3rd RNA Leaders USA taking place 9/4-9/5 in San Diego. Management will also participate in one-on-one investor meetings at the UBS Private Company Virtual Symposium on 9/18-9/19, and the Bank of America Healthcare Trailblazers Private Company Conference taking place 9/25-9/26 in Boston). Read more in our press release. https://bit.ly/3Mi5WC9 #precisionmedicine #ALS, #FTD #FXS #neurodegenerativediseases #neurologicaldiseases
QurAlis to Participate in Upcoming Investor and Industry Conferences in September
https://www.quralis.com
-
QurAlis is thrilled to be named one of the top 10 neuroscience biotechs by Labiotech.eu. It is an honor to be recognized for the work we are doing to help discover and develop effective #precisionmedicines that have the potential to alter the trajectory of #ALS, #FTD, and other #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3MzZ5Ep
10 neuroscience biotech companies you should know about
https://www.labiotech.eu
-
QurAlis reposted this
QurAlis thanks Eikonizo Therapeutics for the #icebukcetchallenge nomination - challenge accepted! We are honored to participate to raise #ALSawareness as part of the 10th Anniversary of the ALS Ice Bucket Challenge. QurAlis' CEO and co-founder Kasper Roet and CTO Hagen Cramer got “soaked” on behalf of QurAlis. In the spirt of community building and to keep the positivity flowing, QurAlis challenges Leal Therapeutics, ProJenX, and NeuroSense Therapeutics to complete the Ice Bucket Challenge. Let’s continue to spread the word for ALS research and a cure! #icebucket10 #fratetrain #precisionmedicine #neurodegenerativediseases
-
QurAlis thanks Eikonizo Therapeutics for the #icebukcetchallenge nomination - challenge accepted! We are honored to participate to raise #ALSawareness as part of the 10th Anniversary of the ALS Ice Bucket Challenge. QurAlis' CEO and co-founder Kasper Roet and CTO Hagen Cramer got “soaked” on behalf of QurAlis. In the spirt of community building and to keep the positivity flowing, QurAlis challenges Leal Therapeutics, ProJenX, and NeuroSense Therapeutics to complete the Ice Bucket Challenge. Let’s continue to spread the word for ALS research and a cure! #icebucket10 #fratetrain #precisionmedicine #neurodegenerativediseases
-
QurAlis reposted this
A recent study published in the Neurology August issue has increased our understanding of #ALS Reversal – a very rare phenomenon leading to patients diagnosed with #ALS or progressive muscular atrophy to show substantial and sustained improvement. The study employed genome-wide association studies and whole-genome sequencing to identify a crucial genetic locus in the IGFBP7 gene. This research uncovered a single nucleotide variant linked to reduced IGFBP7 expression, which may influence the insulin-like growth factor-1 (IGF-1) signaling pathway, potentially offering neuroprotective benefits. Although the study's sample size was limited, the research team concluded that this finding might guide future exploratory investigations of specific mechanisms of ALS disease resistance. The IGF-1 pathway may provide a novel direction in the discovery of potential new treatment approaches for ALS and other #neurodegenerativediseases. Congratulations to the team for this pioneering research –Jesse I. Crayle, MD, Evadnie Rampersaud, PhD, Jason R. Myers, MS, Joanne Wuu, ScM, J. Paul Taylor, MD, PhD, Gang Wu, PhD, Michael Benatar, MBChB, MS, and Richard S. Bedlack, MD, PhD https://bit.ly/4cqrSW5
Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype | Neurology
neurology.org
-
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. We're looking for talented individuals to join us on this exciting journey. Check out our current openings below: https://lnkd.in/gF7-tQhe https://lnkd.in/gTMkN5Gt https://lnkd.in/gHS_JX-x https://lnkd.in/gwGtAm_3 https://lnkd.in/gQ9aBTdB https://lnkd.in/gwss9diN https://lnkd.in/gfgUwNaD https://lnkd.in/gJF8vVMa https://lnkd.in/gAjYbV4P